| DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts D Roulois, HL Yau, R Singhania, Y Wang, A Danesh, SY Shen, H Han, ... Cell 162 (5), 961-973, 2015 | 1264 | 2015 |
| Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression S Chen, G Zhu, Y Yang, F Wang, YT Xiao, N Zhang, X Bian, Y Zhu, Y Yu, ... Nature cell biology 23 (1), 87-98, 2021 | 238 | 2021 |
| Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency P Mehdipour, SA Marhon, I Ettayebi, A Chakravarthy, A Hosseini, Y Wang, ... Nature 588 (7836), 169-173, 2020 | 172 | 2020 |
| The cancer epigenome: exploiting its vulnerabilities for immunotherapy HL Yau, I Ettayebi, DD De Carvalho Trends in cell biology 29 (1), 31-43, 2019 | 96 | 2019 |
| DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T cells HL Yau, E Bell, I Ettayebi, FC de Almeida, GM Boukhaled, SY Shen, ... Molecular cell 81 (7), 1469-1483. e8, 2021 | 62 | 2021 |
| The mitochondrial transacylase, tafazzin, regulates AML stemness by modulating intracellular levels of phospholipids AK Seneviratne, M Xu, JJA Henao, VA Fajardo, Z Hao, V Voisin, GW Xu, ... Cell stem cell 24 (4), 621-636. e16, 2019 | 54 | 2019 |
| B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity R Rahbar, A Lin, M Ghazarian, HL Yau, S Paramathas, PA Lang, ... Cancer Immunology Research 3 (2), 184-195, 2015 | 47 | 2015 |
| An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors K Taylor, HL Yau, A Chakravarthy, B Wang, SY Shen, I Ettayebi, CA Ishak, ... Journal for immunotherapy of cancer 8 (2), 2020 | 44 | 2020 |
| Pharmacological DNA demethylation: Implications for cancer immunotherapy D Roulois, HL Yau, DD De Carvalho Oncoimmunology 5 (3), e1090077, 2016 | 31 | 2016 |
| Spliceosome-targeted therapies induce dsRNA responses CA Ishak, HL Yau, DD De Carvalho Immunity 54 (1), 11-13, 2021 | 10 | 2021 |
| Publisher Correction: Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency (Nature,(2020), 588, 7836,(169-173), 10.1038/s41586-020-2844-1) P Mehdipour, SA Marhon, I Ettayebi, A Chakravarthy, A Hosseini, Y Wang, ... Nature 591 (7850), E20, 2021 | 5 | 2021 |
| Methods to detect endogenous dsRNA induction and recognition I Ettayebi, HL Yau, DD De Carvalho Methods in Enzymology 629, 35-51, 2019 | 4 | 2019 |
| DNA-Demethylating Agents enhance cytolytic activity of CD8+ T Cells and anti-tumor immunity HL Yau, A Chakravarthy, FC Almeida, D Allard, R Singhania, I Ettayebi, ... bioRxiv, 197236, 2017 | 3 | 2017 |
| Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia FA de Castro, P Mehdipour, A Chakravarthy, I Ettayebi, H Loo Yau, ... British Journal of Haematology 204 (1), 206-220, 2024 | 2 | 2024 |
| Abstract CT190: A Phase II basket study of hypomethylating agent oral cc-486 and durvalumab in advanced solid tumors (METADUR) K Taylor, HL Yau, BX Wang, PL Bedard, AR Razak, AR Hansen, ... Cancer Research 79 (13_Supplement), CT190-CT190, 2019 | 2 | 2019 |
| The chromatin and single-cell transcriptional landscapes of CD4 T cells in inflammatory bowel disease link risk loci with a proinflammatory Th17 cell population TS Medina, A Murison, M Smith, GS Kinker, A Chakravarthy, GAF Vitiello, ... Frontiers in immunology 14, 1161901, 2023 | 1 | 2023 |
| DNA-Demethylating Agents Enhance Cytolytic Activity of CD8 T Cells and Anti-Tumor Immunity HL Yau, A Chakravarthy, F Campos de Almeida, D Allard, R Singhania, ... | 1 | 2018 |
| Abstract B053: Characterizing the effects of the DNA methylation inhibitor 5-AZA-CdR during CD8 T cell expansion HL Yau Cancer Immunology Research 4 (11_Supplement), B053-B053, 2016 | 1 | 2016 |
| Measuring the effect of drug treatments on primary human CD8+ T cell activation and cytolytic potential HL Yau, DD De Carvalho STAR protocols 2 (2), 100549, 2021 | | 2021 |
| Epigenetic Therapy as a Primer for Immunotherapy HL Yau University of Toronto (Canada), 2021 | | 2021 |
